“The target safety evaluation was perfect.  Our toxicologist was very happy with the final document as was the project team.  Not only was the document great, it was delivered on time and the turn-around time for the edits was outstanding.  I have no doubt that we will be using your services in the future.”

James Murray, Toxicologist, Sanofi

Leading Global Pharmaceutical Company


“I wanted to let you know that, after including your expert report into the IB, the Health Authority have approved both the IB as well as the clinical protocol amendment switching the contraception method from highly affective to effective, without any further questions or comments.

This is a very good news for the project, and clinical studies can continue as planned. Thank you very much for all your support, it was a great pleasure collaborating with you. I have greatly appreciated your thorough assessment as well as responsive and friendly  manner, and your input made a key difference for the project progression.”

Preclinical Project Manager, Leading Global Pharmaceutical Company

Gilead Sciences


“Working with ApconiX has been effortless! They have provided high quality target safety assessments with a focus on comprehensive interpretation of findings. The information provided has helped contribute to decisions on activities when moving early molecules forward. ApconiX constantly meets or exceeds timelines, while still providing flexibility to fit in last minute requests without impacting previously scheduled work. It has been a pleasure to work with Ruth and her team.”

Gilead Sciences

Blueberry Therapeutics


“The support that we received from the ApconiX team has been excellent and they have helped us both in developing our nonclinical safety thinking and in providing direct support for the clinical trial application. We’re looking forward to continuing our collaboration as we progress our exciting new medicines into later-stage development and hopefully the clinic”

Dr. David Cook, Chief Scientific Officer, Blueberry Therapeutics



“ApconiX has provided hERG data to Redx Pharma from June 2016 to help support our discovery projects. Data turnaround times over this period have been rapid (under 1 week) and this has been critical in progressing projects quickly; outsourcing the assay with this turn-around has had no impact on our “design-make-test” cycle times.

Additionally, ApconiX’s approach is very collaborative providing expert advice on these data as part of their service. Another vital component to this screening is flexibility over compound numbers which enables us to maintain progress during the peaks and troughs of compound supply and prevents delays which can occur if you have to wait to reach a trigger point for submission of an assay.”

Dr Stuart Best, Redx Pharma



“It has been a tremendous pleasure to work with Ruth @ApconiX for the past year. Her in-depth knowledge in toxicology in general and drug discovery/development in specific has contributed significantly to my division’s research in the area of drug-induced liver injury and in vitro to in vivo extrapolation.  I am expecting much great science will come out from the close collaboration with Ruth”

Weida Tong, Director, Division of Bioinformatics and Biostatistics and NCTR/FDA

Sygnature Discovery


“Toxicology and functional electrophysiology assessments are essential aspects of the drug discovery and development process to ensure the safety of a potential drug prior to administration in humans.  The specialists at ApconiX are world renowned scientists in non-clinical safety strategies and their skills will be of great benefit to our clients.  The alliance between Sygnature Discovery and ApconiX will be mutually beneficial and together we can offer a more comprehensive integrated approach to any clients’ drug discovery programme.

We are very much looking forward to working with ApconiX and introducing them to our clients.”

Dr Clewlow, Sygnature Discovery



“We are delighted to have found a flexible way to access specialist technical expertise and operational support to complement our existing internal capabilities to support the ongoing development of our lead product, SFX-01.  We selected this excellent group of providers as our partners as they have a proven track record of working well together and they are all co-located at Alderley Park where we too have a presence.”

Dr Stephen Franklin, Founder and CEO, Evgen Pharma
Go to Top